{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:20:49Z","timestamp":1783484449687,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009226","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T00:00:00Z","timestamp":1369958400000}}],"reference-count":63,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009226.pub2","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T13:42:16Z","timestamp":1369748536000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Rituximab for thyroid-associated ophthalmopathy"],"prefix":"10.1002","author":[{"given":"Neda","family":"Minakaran","sequence":"first","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; Department of Ophthalmology; 162 City Road London UK EC1V 2PD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G","family":"Ezra","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust; Moorfields and UCL Institute of Ophthalmology BMRC; City Road London UK EC1V 2PD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD009226.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"Fassi","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"Fassi","year":"2006","journal-title":"Thyroid"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gut.2007.138305","article-title":"Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease","volume":"57","author":"Fassi","year":"2008","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves' disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2265.2009.03762.x","article-title":"Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids","volume":"72","author":"Krassas","year":"2010","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD009226.pub2-BIB0007|cit7","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid refractory Graves\u2019 orbitopathy","author":"Mitchell","journal-title":"Cinical Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12016-007-8024-3","article-title":"Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy","volume":"34","author":"Bonara","year":"2008","journal-title":"Clinical Reviews in Allergy and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archopthalmol.2011.1215","article-title":"Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action","volume":"130","author":"Salvi","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD009226.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","article-title":"Rituximab for thyroid eye disease","volume":"26","author":"Silkiss","year":"2010","journal-title":"Ophthalmic Plastic and Reconstructive Surgery"},{"key":"10.1002\/14651858.CD009226.pub2-BIB0014|cit14","unstructured":"EUCTR2011-000899-33-SE Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2011-000899-33-SE+\u00a0"},{"key":"10.1002\/14651858.CD009226.pub2-BIB0015|cit15","unstructured":"EUdraCT 2007-003910-33 Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO) www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2007-003910-33"},{"key":"10.1002\/14651858.CD009226.pub2-BIB0016|cit16","unstructured":"NCT00595335 Phase 2\/3 study of rituximab for Graves' ophthalmopathy clinicaltrials.gov\/show\/NCT00595335"},{"issue":"8","key":"10.1002\/14651858.CD009226.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy","volume":"18","author":"Bartalena","year":"2008","journal-title":"Thyroid"},{"issue":"12","key":"10.1002\/14651858.CD009226.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD009226.pub2-BIB0020|cit20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007630.pub2","article-title":"Surgical orbital decompression for thyroid eye disease","author":"Boboridis","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jbspin.2008.08.002","article-title":"Regulatory T cells (Treg) in rheumatoid arthritis","volume":"76","author":"Boissier","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub2-BIB0023|cit23","first-page":"747","article-title":"Graves' ophthalmopathy: current concepts regarding pathogenesis and management","volume":"14","author":"Burch","year":"1993","journal-title":"Endocrine Reviews"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-0029-1220935","article-title":"Current insights into the pathogenesis of Graves' orbitopathy","volume":"41","author":"Eckstein","year":"2009","journal-title":"Hormone and Metabolic Research"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"Fassi","year":"2006","journal-title":"Thyroid"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00004728-197903060-00019","article-title":"Appearance of Graves' disease on orbital computed tomography","volume":"3","author":"Enzmann","year":"1979","journal-title":"Journal of Computer Assisted Tomography"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers","volume":"155","author":"Wiersinga","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jclinpath-2012-200719","article-title":"Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy","volume":"65","author":"Ezra","year":"2012","journal-title":"Journal of Clinical Pathology"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub2-BIB0029|cit29","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/en.2005-1018","article-title":"T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy","volume":"147","author":"Han","year":"2006","journal-title":"Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(03)00032-4","article-title":"B-cell depletion with rituximab - a targeted therapy in Graves' disease and autoimmune thyroiditis","volume":"88","author":"Hasselbach","year":"2003","journal-title":"Immunology Letters"},{"key":"10.1002\/14651858.CD009226.pub2-BIB0032|cit32","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","article-title":"Psychosocial morbidity of Graves' orbitopathy","volume":"63","author":"Kahaly","year":"2005","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Annual of Rheumatological Disease"},{"issue":"11","key":"10.1002\/14651858.CD009226.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2165\/11201110-000000000-00000","article-title":"Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma","volume":"70","author":"Keating","year":"2010","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clim.2009.07.001","article-title":"Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network","volume":"113","author":"Keren","year":"2009","journal-title":"Clinical Immunology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009226.pub2-BIB0037|cit37","first-page":"204","article-title":"Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today","volume":"7","author":"Krassas","year":"2010","journal-title":"Paediatric Endocrinology Reviews"},{"issue":"6011","key":"10.1002\/14651858.CD009226.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/314537a0","article-title":"Antigen-specific interaction between T and B cells","volume":"314","author":"Lanzavecchia","year":"1985","journal-title":"Nature"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells","volume":"127","author":"Liossis","year":"2008","journal-title":"Clinical Immunology"},{"issue":"20","key":"10.1002\/14651858.CD009226.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009226.pub2-BIB0041|cit41","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blinded randomized study","volume":"86","author":"Marroci","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD009226.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clinical Endocrinology"},{"issue":"22","key":"10.1002\/14651858.CD009226.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009226.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1210\/er.2002-0020","article-title":"Current perspective on the pathogenesis of Graves' disease and ophthalmopathy","volume":"24","author":"Prabhakar","year":"2003","journal-title":"Endocrine Reviews"},{"issue":"9","key":"10.1002\/14651858.CD009226.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1745-6215-9-6","article-title":"Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial","volume":"31","author":"Rajendram","year":"2008","journal-title":"Trials"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007114.pub2","article-title":"Orbital radiotherapy for adult thyroid eye disease","author":"Rajendram","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-008-0719-0","article-title":"NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis","volume":"29","author":"Reis","year":"2009","journal-title":"Rheumatology International"},{"key":"10.1002\/14651858.CD009226.pub2-BIB0049|cit49","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"4","key":"10.1002\/14651858.CD009226.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","article-title":"Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates","volume":"131","author":"Salvi","year":"2009","journal-title":"Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.survophthal.2012.10.006","article-title":"B-cell targeted therapy with rituximab for thyroid eye disease: closer to the clinic","volume":"58","author":"Shen","year":"2013","journal-title":"Survey of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD009226.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus Statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Annals of Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD009226.pub2-BIB0054|cit54","first-page":"3428","article-title":"Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture","volume":"81","author":"Sorisky","year":"1996","journal-title":"Journal of Clinical Endrocrinology and Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD009226.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","article-title":"Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments","volume":"54","author":"Terwee","year":"2001","journal-title":"Clinical Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD009226.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nature Reviews Immunology"},{"issue":"9","key":"10.1002\/14651858.CD009226.pub2-BIB0058|cit58","first-page":"2830","article-title":"Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance","volume":"80","author":"Villadolid","year":"1995","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD009226.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1210\/en.2006-0852","article-title":"Targeting B cells in Graves' disease","volume":"147","author":"Wang","year":"2006","journal-title":"Endocrinology"},{"issue":"11","key":"10.1002\/14651858.CD009226.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project","volume":"51","author":"Ware","year":"1998","journal-title":"Journal of Clinical Epidemiology"},{"issue":"17","key":"10.1002\/14651858.CD009226.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD009226.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/105072502761016476","article-title":"Epidemiology and prevention of Graves' ophthalmopathy","volume":"12","author":"Wiersinga","year":"2002","journal-title":"Thyroid"},{"issue":"3","key":"10.1002\/14651858.CD009226.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/WNO.0b013e31814a5ef8","article-title":"Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease","volume":"27","author":"Zoumalan","year":"2007","journal-title":"Journal of Neuro-Opthalmology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd009226.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009226.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:29:51Z","timestamp":1628548191000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD009226.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":63,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009226.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD009226.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]}}}